Muenzer J. The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric onset. Am J Med Genet C Semin Med Genet. 2011;157C(1):3-12.
[2]
Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:3421-3452.
[3]
Clarke LA. Mucopolysaccharidosis Type I. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews. Seattle (WA): University of Washington; 1993-2024.
[4]
Muenzer J, Wraith JE, Clarke LA. International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Pediatrics. 2009;124(6):e1228-e1239.
[5]
Giugliani R, Federhen A, Manuel J, et al. Therapeutic options for the management of mucopolysaccharidosis type II (Hunter syndrome). Dev Med Child Neurol. 2016;58(Suppl 2):28-36.
[6]
Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in severe Hunter syndrome (MPS II): Results of a phase III/IV study. J Pediatr. 2018;203:1-9.
[7]
Scarpa M, Almássy Z, Beck M, et al. Hunter Syndrome European Expert Council. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267-277.
[8]
Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of MPS II patients. Mol Genet Metab. 2011;104(1-2):S22.
[9]
Wraith JE, Scarpa M, Beck M, et al. Recommendations on the diagnosis and management of MPS II (Hunter syndrome). Acta Paediatr. 2008;97(451):5-14.
[10]
Jurecka A, Zacharwoski M, Lugowska A, et al. Diagnosis and management of mucopolysaccharidosis type III (Sanfilippo syndrome). Dev Med Child Neurol. 2015;57(3):221-228.